Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue

Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue

Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has mat...

Full description

Bibliographic Details
Main Authors: Stroh, M, Carlile, DJ, Li, C-C, Wagg, J, Ribba, B, Ramanujan, S, Jin, J, Xu, J, Charoin, J-E, Xhu, Z-X, Morcos, PN, Davis, JD, Phipps, A
Format: Online
Language:English
Published: John Wiley & Sons, Ltd 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592528/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592528/

Similar Items